Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT1 | Q99873 | 1/20 | 1.00 |
| ▸ | NPC1 | O15118 | 2/20 | 0.57 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | SIRT2 | Q8IXJ6 | 3/20 | 0.50 |
| ▸ | SIRT1 | Q96EB6 | 3/20 | 0.50 |
| ▸ | SIRT3 | Q9NTG7 | 3/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | DRD2 | P14416 | 1/20 | 0.49 |
| ▸ | DRD4 | P21917 | 1/20 | 0.49 |
| ▸ | DRD3 | P35462 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14804765 | 0.82 | KDM4E (0.71) | PRMT1NPC1LMNAALDH1A1SIRT2 | |
| SCHEMBL3436249 | 0.81 | PRMT1 (0.68) | PRMT1NPC1LMNAMAPK1ALDH1A1 | |
| SCHEMBL3318522 | 0.81 | PRMT1 (0.68) | PRMT1LMNAMAPK1ALDH1A1TSHR | |
| SCHEMBL10049116 | 0.81 | KDM4E (0.73) | PRMT1NPC1LMNAALDH1A1SIRT2 | |
| SCHEMBL6707329 | 0.81 | PRMT1 (0.67) | PRMT1LMNAMAPK1ALDH1A1TSHR | |
| Iodide SCHEMBL6706501 | 0.80 | PRMT1 (0.66) | PRMT1LMNAMAPK1ALDH1A1TSHR | |
| SCHEMBL27894380 | 0.78 | PRMT1 (0.64) | PRMT1NPC1ALDH1A1SIRT2SIRT1 | |
| SCHEMBL7364367 | 0.78 | PRMT1 (0.64) | PRMT1NPC1LMNAALDH1A1KDM4E | |
| SCHEMBL1618023 | 0.76 | PRMT1 (0.61) | PRMT1LMNAMAPK1ALDH1A1TSHR | |
| SCHEMBL9955066 | 0.75 | PRMT1 (0.60) | PRMT1LMNAMAPK1ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220168329-A1 | COMBINATORIAL DRUG TREATMENT OF CANCER | UNIVERSITY OF VIRGINIA | 2022-06-02 | — | — | US | claimed |
| US-20240110230-A1 | BIOMARKERS FOR CANCER TREATMENT | FOUNDATION MEDICINE, INC. (US) | 2024-04-04 | — | — | US | disclosed |
| EP-4291902-A2 | BIOMARKERS FOR CANCER TREATMENT | Foundation Medicine, Inc. (US) | 2023-12-20 | — | — | EP | disclosed |
| WO-2022174234-A2 | BIOMARKERS FOR CANCER TREATMENT | FOUNDATION MEDICINE, INC. (US) | 2022-08-18 | — | — | WO | disclosed |
| CN-108947879-B | PRMT I type inhibitor and preparation method and application thereof | 中国科学院上海药物研究所 | 2022-06-28 | — | — | CN | disclosed |
| US-20220168329-A1 | COMBINATORIAL DRUG TREATMENT OF CANCER | UNIVERSITY OF VIRGINIA | 2022-06-02 | — | — | US | disclosed |
| US-20220168329-A1 | COMBINATORIAL DRUG TREATMENT OF CANCER | UNIVERSITY OF VIRGINIA | 2022-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220168329-A1 | COMBINATORIAL DRUG TREATMENT OF CANCER | DDIT3, PRMT3, PRMT1 | PRMT1 3/4885NPC1 3527/4885LMNA 3036/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.